Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16150758 | 0.75 | — | — | |
| SCHEMBL16033512 | 0.70 | CYP2C9 (0.41) | CYP2C9 | |
| SCHEMBL2800430 | 0.65 | KDM4E (0.30) | — | |
| SCHEMBL1747877 | 0.65 | CYP2A13 (0.30) | — | |
| Hydrochloric Acid SCHEMBL1761554 | 0.63 | — | — | |
| SCHEMBL678774 | 0.62 | — | — | |
| SCHEMBL7479191 | 0.61 | — | — | |
| SCHEMBL21474602 | 0.60 | — | — | |
| SCHEMBL7422557 | 0.60 | CYP2C9 (0.36) | CYP2C9 | |
| SCHEMBL28886800 | 0.59 | HSD11B1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-03-15 | — | — | US | disclosed |
| US-8076350-B2 | 3H-(4's)-1'-azaspiro[benzofuran-2,4']-tricyclo[3.3.1.13,7]decane; for therapy of memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder; attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076350-B2 | 3H-(4's)-1'-azaspiro[benzofuran-2,4']-tricyclo[3.3.1.13,7]decane; for therapy of memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder; attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2114943-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | Abbott Laboratories (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114943-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | Abbott Laboratories (US) | 2009-11-11 | — | — | EP | disclosed |
| CN-101568541-A | Spirocyclic azaadamantane derivatives and methods of use | ABBOTT LAB (US) | 2009-10-28 | — | — | CN | disclosed |
| WO-2008079570-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079570-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | CYP2C9 143/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | CYP2C9 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.